Longevity is usually presented as a demographic statistic.
For an individual planning retirement, it is something more consequential: an economic uncertainty that changes the investment problem itself.
A retirement portfolio does not merely need to accumulate enough wealth by a particular date. It needs to finance an uncertain stream of future consumption over an uncertain period of time.
Those are different objectives.
And once that distinction is recognised, longevity belongs inside the investment problem rather than sitting outside it as a background assumption.
Wealth at retirement is not the objective
Traditional retirement investment strategies often focus heavily on the accumulation phase.
A worker contributes to a portfolio. Assets grow. Risk is progressively reduced as retirement approaches. Success is frequently expressed as the amount of wealth accumulated at retirement.
But retirement does not end when the accumulation period ends.
It begins.
In Retirement Income Sufficiency through Personalised Glidepaths, published in the Financial Analysts Journal in 2021, Michael E. Drew and Jason M. West argue that the relevant risk is retirement income uncertainty.
Their central distinction is fundamental:
allocating investments to maximise wealth at retirement is not equivalent to allocating investments to satisfy an income objective throughout retirement.
A portfolio can arrive at retirement with an apparently satisfactory balance and still fail to finance the retirement that follows.
Longevity changes the denominator
Consider two otherwise identical individuals retiring with the same assets, spending needs and investment opportunity set.
One requires the portfolio to support 15 years of retirement.
The other requires it to support 35 years.
Those are not merely different forecasts of the same problem.
They are materially different financial problems.
A longer horizon means more years of withdrawals, more inflation exposure, more opportunities for adverse markets, more uncertainty about healthcare and consumption, and a longer period over which the portfolio may need to preserve purchasing power.
It can also create a greater need for growth assets even while the retiree has less capacity to recover from severe losses.
That tension is one reason retirement asset allocation is difficult.
Longevity does not simply increase the amount of money required. It changes the interaction between assets, spending and time.
Sequence matters once money is being withdrawn
During retirement, the order in which investment returns occur can matter substantially.
When no external cash flows occur, changing the order of a given sequence of returns does not change the compound terminal result.
Withdrawals break that symmetry.
Poor investment returns early in retirement can force assets to be sold from a depleted portfolio. Those assets are then unavailable to participate in a subsequent recovery.
The result is sequence-of-returns risk.
A longer retirement horizon does not mechanically imply that every retiree should hold more or less equity. It means that the consequences of allocation and withdrawal decisions must be evaluated over a potentially different liability horizon.
The appropriate question becomes:
How resilient is this retirement-income strategy across plausible combinations of longevity, spending and market outcomes?
That is a scenario problem, not a simple age-based rule.
The glidepath should belong to the individual
Conventional target-date approaches commonly use age as the dominant organising variable.
Age is observable, convenient and relevant.
It is not sufficient.
Drew and West demonstrate that glidepaths can instead be personalised to maximise expected retirement-income sufficiency under a range of assumptions, including longevity risk.
This reframes the glidepath.
Rather than asking:
"What allocation is conventional for someone aged 60?"
we can ask:
"What investment path best supports this individual's retirement-income objective under the risks that matter to this individual?"
Those risks can include salary dynamics before retirement, accumulated wealth, required income, market uncertainty and longevity.
The distinction between a demographic glidepath and a personalised glidepath is therefore not cosmetic.
It reflects a different objective function.
Longevity and asset allocation
It is tempting to turn the longevity relationship into a simple rule:
"If you may live longer, hold more equities."
That would be too crude.
A longer horizon can increase the value of long-term growth. But allocation also depends on spending flexibility, funded status, other income, risk capacity, liquidity requirements, market conditions, bequest objectives and the consequences of loss.
For some households, additional longevity risk may strengthen the case for maintaining growth exposure.
For others, it may increase the importance of secure income, liquidity or downside protection.
For still others, the dominant response may be a change in spending rather than portfolio composition.
The correct conclusion is therefore not that longevity determines an asset allocation.
It is that longevity is one of the variables against which an asset allocation should be tested.
Withdrawals connect the portfolio to the life
The same principle applies to spending.
A fixed withdrawal that is sustainable over 20 years may be unsustainable over 40.
But reducing spending aggressively to protect against an extremely long life can also produce poor outcomes: the retiree may unnecessarily suppress consumption and leave wealth unused.
Retirement planning therefore contains an unavoidable trade-off between consumption today, resilience tomorrow and wealth remaining at death.
Longevity uncertainty sits directly inside that trade-off.
A useful planning framework should consequently be able to explore different withdrawal policies rather than merely project a single spending path.
Questions might include:
- What happens if retirement lasts ten years longer than assumed?
- How much spending flexibility is available after poor early returns?
- How does a higher defensive allocation affect long-horizon income sufficiency?
- What growth exposure is needed to preserve purchasing power?
- At what point does the portfolio become vulnerable to depletion?
- How much wealth remains available for an intended bequest?
These are interconnected questions.
Estate planning is the other side of longevity risk
Longevity also changes the estate problem.
If an individual dies earlier than expected, more capital may remain available for beneficiaries.
If the individual lives substantially longer, more capital may be consumed financing retirement.
Estate capacity is therefore partly contingent on the same uncertain horizon that drives retirement-income risk.
This creates a direct connection between retirement planning and estate planning.
A bequest objective cannot be considered entirely independently of spending, asset allocation and longevity because all four make claims on the same balance sheet.
Bioanalytix therefore treats estate outcomes as part of the connected planning problem rather than as a separate calculation performed at the end.
Where biological evidence enters
This raises an unusual question.
If longevity matters to portfolio design, could better biological information improve financial planning?
Potentially — but only if the claim is framed correctly.
Genetic evidence does not reveal an individual's date of death.
It may contribute information about biological pathways, disease susceptibility and traits associated with ageing and longevity.
The economic value of such information therefore does not require perfect prediction.
Instead, consider a weaker proposition.
Suppose biological evidence changes our assessment of which longevity or health scenarios deserve serious consideration.
If those scenarios produce materially different retirement outcomes, the information can be relevant to planning even though lifespan remains uncertain.
This gives us the chain:
biological evidence → longevity and health uncertainty → planning horizon → retirement-income requirements → portfolio and withdrawal scenarios → estate outcomes
The biological evidence does not select an investment.
It changes the assumptions under which the financial strategy can be stress-tested.
Information has value when it changes a decision
This is an important economic point.
Information does not need to eliminate uncertainty to have value.
It needs to improve the decisions made under uncertainty.
If new information leaves every plausible planning decision unchanged, its economic value may be small.
If it changes the range of scenarios that a rational decision-maker should consider, it may be valuable even when considerable uncertainty remains.
This is the conceptual bridge between biological evidence and financial planning.
Bioanalytix does not ask genetics to do something genetics cannot do.
It asks whether better information about the person can improve the assumptions used to model the person's future.
From population averages to personalised uncertainty
Population averages are indispensable.
They are also averages.
Individuals differ in wealth, earnings, spending, family structure, health, genetics, preferences, retirement age and objectives.
A planning system that ignores those differences can be precise mathematically while remaining poorly targeted economically.
Personalisation does not mean pretending uncertainty disappears.
It means modelling the uncertainty that is relevant to the individual rather than relying unnecessarily on the characteristics of an average person.
That is the deeper implication of personalised retirement research.
The objective is not to know the future.
It is to construct a financial strategy that remains useful across the futures that matter.
A different question for retirement planning
The conventional question is often:
"How much do I need to retire?"
A better question may be:
"What strategy gives me the greatest resilience across the different lengths and forms my retirement could take?"
Once framed this way, longevity is no longer merely an actuarial input.
It affects spending, portfolio horizon, asset allocation, withdrawal policy, risk capacity and estate outcomes.
That makes longevity risk an investment problem.
And it explains why understanding the individual — biologically as well as financially — may ultimately matter to the design of the plan.
References
Drew, M. E. & West, J. M. (2021). Retirement Income Sufficiency through Personalised Glidepaths. Financial Analysts Journal, 77(2), 5–20. https://doi.org/10.1080/0015198X.2021.1877981
Christensen, K., Johnson, T. E. & Vaupel, J. W. (2006). The quest for genetic determinants of human longevity: challenges and insights. Nature Reviews Genetics, 7, 436–448. https://doi.org/10.1038/nrg1871
Melzer, D., Pilling, L. C. & Ferrucci, L. (2020). The genetics of human ageing. Nature Reviews Genetics, 21, 88–101. https://doi.org/10.1038/s41576-019-0183-6